# Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations

> **NCT06062823** · PHASE2 · RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 35 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Afatinib 40 MG

## Key facts

- **NCT ID:** NCT06062823
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-25
- **Primary completion:** 2026-10
- **Final completion:** 2026-12
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06062823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06062823, "Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06062823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*